Lordick Florian, Ott Katja, Weitz Jürgen, Jäger Dirk
University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany.
Expert Opin Biol Ther. 2008 Sep;8(9):1407-15. doi: 10.1517/14712598.8.9.1407.
Gastric cancer is a condition with a high medical need. Even after R0 resection the rate of peritoneal and other distant site recurrences is high. Novel therapeutic approaches include trifunctional antibodies (trAb) that recruit and activate different types of immune effector cells at the tumour site. The trAb catumaxomab has dual antigen specificity for epithelial cell adhesion molecule and CD3 and binds to Fcgamma-receptor-positive accessory cells. Intraperitoneal administration of catumaxomab in patients with malignant ascites due to epithelial cancer significantly increased puncture-free survival.
To review the mode of action of catumaxomab and describe clinical data regarding the emerging role of catumaxomab in the treatment of patients with gastric cancer. A summary of completed and ongoing clinical trials including patients with gastric cancer is given.
Catumaxomab is a promising approach in the treatment of patients with gastric cancer.
胃癌是一种医疗需求很高的疾病。即使进行了R0切除，腹膜及其他远处部位的复发率仍很高。新型治疗方法包括三功能抗体（trAb），其可在肿瘤部位募集并激活不同类型的免疫效应细胞。三功能抗体卡妥索单抗对上皮细胞黏附分子和CD3具有双重抗原特异性，并与Fcγ受体阳性辅助细胞结合。对上皮癌所致恶性腹水患者腹腔内给予卡妥索单抗可显著提高无穿刺生存期。
综述卡妥索单抗的作用机制，并描述有关卡妥索单抗在胃癌治疗中新兴作用的临床数据。给出了包括胃癌患者在内的已完成和正在进行的临床试验总结。
卡妥索单抗是治疗胃癌患者的一种有前景的方法。
